Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.
about
Initial sequence and comparative analysis of the cat genomeDNA testing in neurologic diseasesPurification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinaseGenetic testing in domestic catsDecreased performance in IDUA knockout mouse mimic limitations of joint function and locomotion in patients with Hurler syndromeRadiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type IFeline genetics: clinical applications and genetic testing.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis IA review of gene therapy in canine and feline models of lysosomal storage disorders.Gene therapy for lysosomal storage diseases (LSDs) in large animal models.Animal models for mucopolysaccharidosis disorders and their clinical relevance.Large animal models of neurological disorders for gene therapy.Bone marrow transplantation for feline mucopolysaccharidosis I.Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.DNA mutations of the cat: the good, the bad and the ugly.Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.Glutamic acid 160 is the acid-base catalyst of beta-xylosidase from Bacillus stearothermophilus T-6: a family 39 glycoside hydrolase.
P2860
Q22065736-9CD1FFD9-583C-437C-8EBF-276F2110F326Q26851653-B1E52F70-F034-45CC-BCBD-C8E329F165F7Q28180283-EC875110-5512-4643-860A-1B0B44A1BEB5Q28710025-748E141E-0929-4197-8DD4-2D53DF7BB7B1Q30665510-F0F21AFE-9A40-4255-B5B5-F1231DB903CFQ33579453-4D5A75D2-5F1E-44BC-8B08-C766160DADC0Q34384047-2F4B48EA-DB67-4092-B10B-CDB5A54CF2A8Q34777085-C743D835-FE28-4279-9196-99366BB61512Q35600310-A71515AE-04B6-4AA8-BEE7-C4C786B2A3AFQ35894676-709B21A6-BE02-46D9-8411-6DAF22A9BEBEQ35923476-16E97B77-22FE-4E95-823D-B63D7BEF2D19Q36772983-8E6BD787-00C6-4ED4-981D-FFFC0DF2AE22Q37265519-63E56412-7834-4E37-A426-35106E1A3D63Q37330939-E7B8756F-FBEE-4C28-AF2E-67C7D6FD3509Q37480537-41A57290-6F9E-4493-BDE2-0017C9C2C7C5Q38363409-E763CEA5-50D8-4561-B447-B5D2E9E36D5DQ38853824-76CE5BA0-D922-49F5-9047-7DD8A8E24D5BQ40663776-8AFA45A6-2965-4409-B514-0791E40195BDQ43588692-ACEC6DDF-2B55-4BB9-9443-40F7EF78D7A9
P2860
Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Identification and characteriz ...... ysaccharidosis type I in cats.
@ast
Identification and characteriz ...... ysaccharidosis type I in cats.
@en
type
label
Identification and characteriz ...... ysaccharidosis type I in cats.
@ast
Identification and characteriz ...... ysaccharidosis type I in cats.
@en
prefLabel
Identification and characteriz ...... ysaccharidosis type I in cats.
@ast
Identification and characteriz ...... ysaccharidosis type I in cats.
@en
P2093
P356
P1476
Identification and characteriz ...... ysaccharidosis type I in cats.
@en
P2093
Desnick RJ
Haskins ME
Schuchman EH
Simonaro CM
P304
P356
10.1006/MGME.1999.2860
P577
1999-06-01T00:00:00Z